Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials-Reference-Cited by-同舟云学术

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

Published:2011-12 Issue:3 Volume:74 Page:469-473
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ku Geoffrey Y.,Haaland Benjamin A.,de Lima Lopes Gilberto

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas;Karamouzis;JAMA,2007

2. Growth factor receptor tyrosine kinases;Yarden;Annu Rev Biochem,1988

3. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas;Volm;Br J Cancer,1998

4. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival;Brabender;Clin Cancer Res,2001

5. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis;Hirsch;J Clin Oncol,2003

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consumer willingness to purchase hydrogen fuel cell vehicles：A meta-analysis of the literature;International Journal of Hydrogen Energy;2024-01

2. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report;Journal of Thoracic Disease;2023-07

3. The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC;International Immunopharmacology;2023-03

4. Precious Gene: The Application of RET-Altered Inhibitors;Molecules;2022-12-13

5. PD-1 Blockade Plus Chemotherapy for EGFR-Mutant, EGFR Tyrosine Kinase Inhibitor-Pretreated Non-Small Cell Lung Cancer: A Multicenter Retrospective Study on Efficacy and Biomarker Exploration;SSRN Electronic Journal;2022